Abstract: A process for the prepartion of 3-[4-(4-oxo-1,4-dihydropyridin-1-yl)benzoyl]butanoic acid which comprises the reaction of 3-(4-fluorobenzoyl)butanoic acid with 4-hydroxypyridine under aqueous conditions in the presence of a base.
Type:
Grant
Filed:
January 29, 1988
Date of Patent:
November 1, 1988
Assignee:
Smith Kline & French Laboratories Limited
Inventors:
Michael B. Mitchell, Kiritkant D. Pancholi
Abstract: A method of inhibiting the production of interleukin-1 by monocytes in a human in need thereof which comprises administering to such human an effective interleukin-1 production inhibiting amount of a 4,5-diaryl-2(substituted)imidazole.
Type:
Grant
Filed:
August 19, 1986
Date of Patent:
October 25, 1988
Assignee:
SmithKline Beckman Corporation
Inventors:
Paul E. Bender, Don E. Griswold, Nabil Hanna, John C. Lee
Abstract: A method of inhibiting the production of interleukin-1 by monocytes and/or macrophages in a human in need thereof which comprises administering to such human an effective interleukin-1 production inhibiting amount of a 2-2'-[1,3-propan-2-onediyl-bis(thio)]bis-1H-imidazole or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
August 19, 1986
Date of Patent:
October 18, 1988
Assignee:
SmithKline Beckman Corporation
Inventors:
Paul E. Bender, Don E. Griswold, Nabil Hanna, John C. Lee
Abstract: A novel process for the isolation and purification of vancomycin class antibiotics which utilized affinity chromatography by the formation of a sorption complex between the antibiotic and an immobilizing ligand selected from -D-alanyl-D-alanine or -X-D-alanyl-D-alanine, wherein X is an amino acid radical and the novel affinity chromatography sorbent employed therein are disclosed.
Type:
Grant
Filed:
February 4, 1987
Date of Patent:
October 18, 1988
Assignee:
Smithkline Beckman Corporation
Inventors:
Robert D. Sitrin, Kenneth M. Snader, Gail F. Wasserman
Abstract: This invention relates to 2- and 4-pyrimidinylmethylsulphinyl(and thio)benzimidazoles in which the pyrimidyl group is substituted by an optionally substituted amino group. These compounds inhibit exogenously and endogenously stimulated gastric acid secretion.
Type:
Grant
Filed:
February 14, 1986
Date of Patent:
October 11, 1988
Assignee:
Smith Kline & French Laboratories Limited
Abstract: The compounds represented by the formula (I) ##STR1## wherein n is 1 or 2; m is 0, 1 or 2; p is 9, 10, 11, 12 or 13; X is hydrogen or hydroxyl; R is hydroxyl or amino; R.sub.1 is hydrogen, amino or ##STR2## and R.sub.2 is hydroxyl, amino, ##STR3## with the proviso that when m is 0, R.sub.1 is hydrogen or pharmaceutically acceptable salts thereof have been found to be leukotriene antagonists and useful in the treatment of diseases in which leukotrienes are a factor, such as asthma.
Abstract: Potent DBH Inhibitors having the formula: ##STR1## wherein R is --CO.sub.2 H or --CH.sub.2 NHR.sup.1 can be used to inhibit DBH activity in mammals.
Type:
Grant
Filed:
April 16, 1985
Date of Patent:
September 20, 1988
Assignee:
SmithKline Beckman Corporation
Inventors:
James S. Frazee, Carl Kaiser, Lawrence I. Kruse
Abstract: The invention relates to a class of 3,4-diamino-1,2,5-thiadiazole-1-oxides which have histamine H.sub.1 -antagonist activity. A preferred compound of the invention is 3-[3-(5-bromo-3-methylpyrid-2-ylamino)-propylamino]-4-amino-1,2,5-thiadiaz ole-1-oxide.
Type:
Grant
Filed:
June 11, 1986
Date of Patent:
September 13, 1988
Assignee:
Smith Kline & French Laboratories Limited
Abstract: Compounds having the formula ##STR1## are .beta.-adrenergic receptor antagonists. Also disclosed are pharmaceutical compositions and methods for producing .beta.-adrenergic receptor antagonistic activity in animals including man.
Abstract: Antitumor pharmaceutical compositions and methods for treating tumors employing .alpha.,.omega.-bis(disubstitutedphosphino)hydrocarbon derivatives or [.alpha.,.omega.-bis(disubstituted phosphino)hydrocarbon] digold(I), digold(III), disilver(I), and dicopper(I) derivatives are disclosed.
Type:
Grant
Filed:
April 2, 1985
Date of Patent:
August 23, 1988
Assignee:
SmithKline Beckman Corporation
Inventors:
David T. Hill, Randall K. Johnson, Christopher K. Mirabelli
Abstract: Vasopressin antagonists which have a dipeptide tail composed of a neutral and basic amino acid unit demonstrate potent V.sub.1 and V.sub.2 -antagonist activity. Two species of this invention, which are prepared by solid phase peptide synthesis, are [1-(.beta.-mercapto-.beta.,.beta.-cyclopentamethylene propionic acid)-2-(O-ethyl)-D-tyrosine-4-valine-7-tyrosine-8-arginine-9-desglycine]- vasopressin and [1-(.beta.-mercapto-.beta.,.beta.-cyclopentamethylenepropionic acid)-2-(O-ethyl)-D-tyrosine-4-valine-7-arginine-8-tyrosine-9-desglycine]- vasopressin.
Abstract: The invention relates to cyanoalkanimidamido derivatives that have utility as cardiac stimulants. A compound of the invention is 6-[4-(N.sup.2 -cyanoethanimidamido)phenyl]-5-methyl-4,5-dihydro-3(2H)-pyridazinone.
Type:
Grant
Filed:
February 10, 1987
Date of Patent:
August 23, 1988
Assignee:
Smith Kline & French Laboratories Limited
Abstract: This invention relates to chemical compounds which have selective thyromimetic activity. A compound of this invention is 3,5-dibromo-3'-[6-oxo-3(1H)-pyridazinylmethyl]-thyronine.
Type:
Grant
Filed:
January 14, 1986
Date of Patent:
August 23, 1988
Assignee:
Smith Kline & French Laboratories Ltd.
Inventors:
David Ellis, John C. Emmett, Anthony H. Underwood, Paul D. Leeson
Abstract: The invention relates to cyanoalkanimidamido derivatives that have utility as cardiac stimulants. A compound of the invention is 6-[4-(N.sup.2 -cyanopropanimidamido)phenyl]-5-methyl-4,5-dihydro-3(2H)-pyridazinone.
Type:
Grant
Filed:
March 26, 1986
Date of Patent:
August 23, 1988
Assignee:
Smith Kline & French Laboratories Limited
Abstract: Pharmaceutical compositions containing an effective, tumor cell growth-inhibiting amount of such a compound, and a method for treating tumor cells sensitive to such a di-gold phosphine compound which comprises administering a tumor cell growth-inhibiting amount of such a compound to an animal afflicted by said tumor cells.
Abstract: Methods of tracking cells in vivo and for determining in vivo cell lifetimes. Cells are labelled with cyanine dyes and detection is by measuring fluorescence, absorbance, or by detecting nuclear magnetic resonance probes included in the cyanine dyes. Using the invented methods, for example, red blood cell and platelet lifetimes are determined. Also, cells are tracked to determine sites of primary or metastatic tumors, or sites of occult infection. Further, rates at which cells pass through vessels is used to determine blood vessel patency and platelet aggregation.
Abstract: Potent dopamine-.beta.-hydroxylase inhibitors having the Formula ##STR1## that are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmaceutical compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-.beta.-hydroxylase activity in mammals. Also disclosed are novel intermediates useful in preparing the presently invented inhibitors.
Type:
Grant
Filed:
March 24, 1987
Date of Patent:
August 9, 1988
Assignee:
SmithKline Beckman Corporation
Inventors:
Joseph A. Finkelstein, Lawrence I. Kruse, Thomas B. Leonard
Abstract: Potent dopamine-.beta.-hydroxylase inhibitors having the Formula: ##STR1## which are useful to inhibit dopamine-.beta.-hydroxylase activity, pharmaceutical compositions including these inhibitors, and methods of using these inhibitors to inhibit dopamine-.beta.-hydroxylase activity in mammals. Also disclosed are novel intermediates useful in preparing the presently invented inhibitors.
Type:
Grant
Filed:
October 7, 1986
Date of Patent:
August 2, 1988
Assignee:
SmithKline Beckman Corporation
Inventors:
Carl Kaiser, Lawrence I. Kruse, Stephen T. Ross